The COVID-19 vaccine being developed by Oxford University is up to 90% effective in preventing COVID-19, interim analysis of trial data suggests.
Three of the UK’s largest pharmacy multiples have suspended online bookings for flu vaccinations owing to high demand.
Early trial results suggest tocilizumab significantly improves outcomes for critically ill COVID-19 patients
The rheumatoid arthritis drug tocilizumab significantly improves outcomes for critically ill patients with severe COVID-19, early findings from the Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia have suggested.
Closures in 2019/2020 have resulted in the lowest number of community pharmacies in England since 2015/2016.
The UK’s largest pharmacy multiple Boots is “in conversations” with NHS England about how it can help provide COVID-19 vaccines to patients, it has said.
Delivery of a COVID-19 vaccine to the public will require the participation of “as many of the workforce who are trained in vaccination as possible” from community pharmacy, an NHS England official has said.
Healthcare professionals should actively seek to understand individual patients’ perspectives on polypharmacy and its challenges, research in BMJ Open has concluded.
Fremanezumab safe and effective for preventing migraine over longer term, study suggestsSubscription
Patients with migraine continue to benefit from preventive treatment with fremanezumab over the longer term, with sustained reductions in monthly migraine and headache days, a study in Neurology has suggested.
Routine use of non-steroidal anti-inflammatory drugs might confer “modest” survival benefit for patients hospitalised with COVID-19 and is not associated with poorer outcomes, the results of a study published in the Journal of Clinical Medicine have suggested.
The clinical and microbiological outcomes of cefiderocol, a new antibiotic, were similar to the best available therapy for patients with life-threatening carbapenem-resistant infections, a phase III study has suggested.
Many patients who contract COVID-19 have detectable lung dysfunction 12 weeks after hospital discharge, results have suggested.
Addition of baricitinib to mainstay of treatment improves signs and symptoms of atopic dermatitis, study findsSubscription
Adding the oral selective Janus kinase 1 and 2 inhibitor, baricitinib, to topical corticosteroid treatment significantly improves the signs and symptoms of moderate-to-severe atopic dermatitis, a phase III study in JAMA Dermatology has suggested.